NUCRYST Pharmaceuticals Corp.

NUCRYST Pharmaceuticals develops, manufactures and commercializes medical products that fight infection and inflammation using its patented atomically disordered nanocrystalline silver technology. NUCRYST is one of the first companies to apply nanotechnology, the science of extremely small materials, into profitable and clinically proven medical products.

Wound care products - SILCRYST business

Advanced wound care products with the company’s SILCRYST™ coatings are sold by Smith & Nephew plc under an exclusive license in over 30 countries under its Acticoat™ trademark.

Acticoat™ products compete in the advanced wound care products market which is projected to grow to US$3.1 billion by 2011.

Acticoat™ products are used for a wide variety of wound types by hospitals, clinics, burn centres, doctors' offices, home healthcare agencies and nursing homes.


Smith & Nephew’s Acticoat™ dressings with SILCRYST™ nanocrystals

• Acticoat™ 3/Acticoat™ Burn for the treatment of wounds requiring up to three days of sustained antimicrobial activity
• Acticoat™ 7 for wounds requiring up to seven days of substantial antimicrobial activity
• Acticoat™ Absorbent for wounds with moderate to excess fluid, or exudate, requiring up to three days of sustained antimicrobial activity
• Acticoat™ Moisture Control for wounds with light to moderate exudate requiring up to seven days of sustained antimicrobial activity

• Acticoat™ Site for use around transcutaneous devices for up to seven days of antimicrobial activity

Potential pharmaceutical products

Many companies first identify a disease and then spend many years and several millions of dollars searching for and experimenting with drug candidates to treat the identified condition. This traditional process can take decades and cost hundreds of millions of dollars.

NUCRYST already has a commercially proven technology and does not have to go through the costly and timely drug discovery process. Instead, NUCRYST focuses on finding indications for its nanocrystalline technology based on patient need and market potential. NUCRYST’s development path should take less time at a fraction of what it costs to develop drugs taking the traditional route.

NUCRYST is developing innovative pharmaceutical products to address medical conditions that are characterized by both infection and inflammation. NUCRYST has developed its nanocrystalline silver in a powder form for use as an active pharmaceutical ingredient, or API, known as NPI 32101.

The company is currently exploring new NPI 32101 product opportunities in dermatology and gastroenterology.

  www.nucryst.com